Product How it works Pricing Blog FAQ About Contact
AbCellera Biologics

AbCellera Biologics (NASDAQ: ABCL) net income

AbCellera Biologics reported a net loss of $146.4m for fiscal 2025; in fiscal 2024 it reported a net loss of $162.9m. Earnings per share were −$0.49.

AbCellera Biologics's best year of the last 6 was fiscal 2022. It reported a loss in 3 of those 6 years.

Net income, in millions of US dollars118.92020153.52021158.52022-146.42023-162.92024-146.42025
Embed this chart

Copy this code into your website or blog. The chart updates with each new annual report.

Net income by fiscal year

Fiscal yearNet incomeChangeNet marginEarnings per share
2025−$146.4m—−194.9%−$0.49
2024−$162.9m—−564.8%−$0.55
2023−$146.4m−192.4%−385.0%−$0.51
2022$158.5m+3.3%32.7%$0.56
2021$153.5m+29.1%40.9%$0.56
2020$118.9m—51.0%$0.53

The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.

AbCellera Biologics net income compared with its sector

By net income for its latest fiscal year, AbCellera Biologics ranks 380th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of AbCellera Biologics, −194.9%.

RankCompanyNet incomeNet margin
378thCharles River Laboratories−$144.3m−3.6%
379thAmylyx Pharmaceuticals−$144.7m—
380thAbCellera Biologics−$146.4m−194.9%
381stCaribou Biosciences−$148.1m−1,327.4%
382ndUroGen Pharma−$153.5m−139.8%

Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.

Questions about the net income of AbCellera Biologics

How much did AbCellera Biologics earn in fiscal 2025?
AbCellera Biologics reported a net loss of $146.4m for fiscal 2025. In fiscal 2024 it reported a net loss of $162.9m.
What are the earnings per share of AbCellera Biologics?
They were −$0.49 in fiscal 2025, compared with −$0.55 in fiscal 2024.
What was the most profitable year for AbCellera Biologics?
Of its last 6 fiscal years, fiscal 2022, with $158.5m.
Where does AbCellera Biologics rank in its sector by net income?
It ranks 380th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
Where do the figures for AbCellera Biologics come from?
From the annual report (Form 10-K) that AbCellera Biologics files with the SEC, the US securities regulator. Each fiscal year links to its filing.

Where each figure comes from

From the annual report (Form 10-K) that AbCellera Biologics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020. More on AbCellera Biologics: the AbCellera Biologics page · annual accounts · revenue · insider transactions.

Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.